Company intelligence / Profile preview

Shijiazhuang Yuanmai Biotechnology

Shijiazhuang, Hebei, China

Ownership: Private
Development stage: Other

Overview

Shijiazhuang Yuanmai Biotechnology holds a license from Medivir to register, manufacture and commercialize the topical antiviral Xerclear (acyclovir + hydrocortisone) for labial herpes in China, with obligations for minimum sales and royalty payments to Medivir after marketing approval and local production.[11][6][15][4]

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Medivir

Beyond the preview

Go deeper on Shijiazhuang Yuanmai Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shijiazhuang Yuanmai Biotechnology.

Explore the full profile